• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The Best Supportive Care in Stage III Non-Small-Cell Lung Cancer.Ⅲ期非小细胞肺癌的最佳支持治疗。
Curr Oncol. 2023 Dec 29;31(1):183-202. doi: 10.3390/curroncol31010012.
2
Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.用于经手术或根治性放疗治疗的Ⅰ至Ⅲ期非小细胞肺癌的免疫疗法(不包括检查点抑制剂)。
Cochrane Database Syst Rev. 2017 Dec 16;12(12):CD011300. doi: 10.1002/14651858.CD011300.pub2.
3
Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer.不可切除 III 期非小细胞肺癌放化疗后免疫相关肺炎及随后的免疫检查点阻断。
Clin Lung Cancer. 2020 Sep;21(5):e435-e444. doi: 10.1016/j.cllc.2020.02.025. Epub 2020 Mar 9.
4
Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.免疫检查点抑制剂联合放化疗治疗不可切除 III 期非小细胞肺癌。
Lung Cancer. 2019 Aug;134:259-267. doi: 10.1016/j.lungcan.2019.05.027. Epub 2019 May 29.
5
Variation Between Multidisciplinary Tumor Boards in Clinical Staging and Treatment Recommendations for Patients With Locally Advanced Non-small Cell Lung Cancer.多学科肿瘤委员会在局部晚期非小细胞肺癌患者临床分期和治疗建议方面的差异。
Chest. 2020 Dec;158(6):2675-2687. doi: 10.1016/j.chest.2020.07.054. Epub 2020 Jul 30.
6
Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.手术或放疗根治性治疗的 I 期至 III 期非小细胞肺癌的免疫治疗(不包括检查点抑制剂)。
Cochrane Database Syst Rev. 2021 Dec 6;12(12):CD011300. doi: 10.1002/14651858.CD011300.pub3.
7
Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.在考虑到美国医疗保健系统的情况下,durvalumab 巩固治疗与放化疗后不进行巩固治疗在 III 期非小细胞肺癌中的成本效果和预算后果分析。
JAMA Oncol. 2019 Mar 1;5(3):358-365. doi: 10.1001/jamaoncol.2018.5449.
8
The role of chemoradiotherapy and immunotherapy in stage III NSCLC.放化疗和免疫治疗在 III 期 NSCLC 中的作用。
Pathol Oncol Res. 2024 Apr 19;30:1611716. doi: 10.3389/pore.2024.1611716. eCollection 2024.
9
Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach.在非小细胞肺癌的诊断和治疗决策中导航:多学科团队方法的专家评论。
Oncologist. 2021 Feb;26(2):e306-e315. doi: 10.1002/onco.13586. Epub 2020 Nov 21.
10
Patterns of care for stage III non-small cell lung cancer in Australia.澳大利亚III期非小细胞肺癌的治疗模式
Asia Pac J Clin Oncol. 2019 Jun;15(3):93-100. doi: 10.1111/ajco.13140. Epub 2019 Mar 14.

引用本文的文献

1
Cancer immunotherapy nursing care from 2004 to 2023: a bibliometric analysis.2004年至2023年癌症免疫治疗护理:文献计量分析
Front Oncol. 2025 Jun 16;15:1508029. doi: 10.3389/fonc.2025.1508029. eCollection 2025.
2
The role of nursing in enhancing quality of life for lung cancer patients receiving targeted and immunotherapy: Challenges, opportunities, and future directions.护理在提高接受靶向治疗和免疫治疗的肺癌患者生活质量中的作用:挑战、机遇与未来方向。
Hum Vaccin Immunother. 2025 Dec;21(1):2506302. doi: 10.1080/21645515.2025.2506302. Epub 2025 May 20.
3
Real-World Survival Impact of New Treatment Strategies for Lung Cancer: A 2000-2020 French Cohort.肺癌新治疗策略的真实世界生存影响:一项2000 - 2020年法国队列研究。
Cancers (Basel). 2024 Aug 5;16(15):2768. doi: 10.3390/cancers16152768.

本文引用的文献

1
Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment.不可切除的 III 期非小细胞肺癌患者的真实世界历程:疾病分期与治疗的当前困境
J Clin Med. 2022 Mar 21;11(6):1738. doi: 10.3390/jcm11061738.
2
The importance of protein sources to support muscle anabolism in cancer: An expert group opinion.癌症患者肌肉合成代谢支持中蛋白质来源的重要性:专家组观点。
Clin Nutr. 2022 Jan;41(1):192-201. doi: 10.1016/j.clnu.2021.11.032. Epub 2021 Nov 29.
3
Examining guidelines and new evidence in oncology nutrition: a position paper on gaps and opportunities in multimodal approaches to improve patient care.探讨肿瘤营养学中的指南和新证据:改善患者护理的多模式方法中存在的差距和机遇的立场文件。
Support Care Cancer. 2022 Apr;30(4):3073-3083. doi: 10.1007/s00520-021-06661-4. Epub 2021 Nov 23.
4
Sarcopenia is associated with poor prognosis after chemoradiotherapy in patients with stage III non-small-cell lung cancer: a retrospective analysis.肌肉减少症与Ⅲ期非小细胞肺癌患者放化疗后的不良预后相关:一项回顾性分析。
Sci Rep. 2021 Jun 4;11(1):11882. doi: 10.1038/s41598-021-91449-z.
5
ESPEN practical guideline: Clinical Nutrition in cancer.ESPEN 实践指南:癌症患者的临床营养。
Clin Nutr. 2021 May;40(5):2898-2913. doi: 10.1016/j.clnu.2021.02.005. Epub 2021 Mar 15.
6
A Canadian Perspective on the Challenges for Delivery of Curative-Intent Therapy in Stage III Unresectable Non-Small Cell Lung Cancer.加拿大视角下 III 期不可切除非小细胞肺癌根治性治疗的挑战。
Curr Oncol. 2021 Apr 24;28(3):1618-1629. doi: 10.3390/curroncol28030151.
7
Does sarcopenia affect postoperative short- and long-term outcomes in patients with lung cancer?-a systematic review and meta-analysis.肌肉减少症是否会影响肺癌患者术后的短期和长期预后?一项系统评价和荟萃分析。
J Thorac Dis. 2021 Mar;13(3):1358-1369. doi: 10.21037/jtd-20-3072.
8
Therapeutic results and prognostic factors of stage III NSCLC: a population-based study in Tunisia.III 期非小细胞肺癌的治疗结果和预后因素:突尼斯的一项基于人群的研究。
Exp Oncol. 2021 Mar;43(1):61-66. doi: 10.32471/exp-oncology.2312-8852.vol-43-no-1.15787.
9
Improving Care for Patients With Stage III or IV NSCLC: Learnings for Multidisciplinary Teams From the ACCC National Quality Survey.改善 III 期或 IV 期 NSCLC 患者的护理:来自 ACCC 国家质量调查的多学科团队的经验教训。
JCO Oncol Pract. 2021 Aug;17(8):e1120-e1130. doi: 10.1200/OP.20.00899. Epub 2021 Mar 9.
10
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.

Ⅲ期非小细胞肺癌的最佳支持治疗。

The Best Supportive Care in Stage III Non-Small-Cell Lung Cancer.

机构信息

Medical Oncology Department, AC Camargo Cancer Center, São Paulo 01509-001, Brazil.

Nurse Navigator Department, AC Camargo Cancer Center, São Paulo 01509-001, Brazil.

出版信息

Curr Oncol. 2023 Dec 29;31(1):183-202. doi: 10.3390/curroncol31010012.

DOI:10.3390/curroncol31010012
PMID:38248097
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10814676/
Abstract

Lung cancer is a major cause of cancer deaths worldwide. Non-small-cell lung cancer (NSCLC) represents most lung cancer cases, and approximately one-third of patients present with stage III disease at diagnosis. As multiple treatment plans can be adopted for these patients depending on tumor size and nodal staging, stage III NSCLC management is challenging. Over the past decades, multidisciplinary teams (MDTs) have been implemented in healthcare services to coordinate actions among the different health care professionals involved in cancer care. The aim of this review was to discuss real-world evidence of the impact of MDTs on stage III NSCLC management, survival, and quality of life. Here, we performed a literature review to investigate the role of nutrition and navigational nursing in NSCLC care and the influence of MDTs in the choice of treatment plans, including immunotherapy consolidation, and in the management of chemotherapy and radiotherapy-related adverse events. We also performed a mapping review to identify gaps in the implementation of cancer care MDTs in healthcare services around the world.

摘要

肺癌是全球癌症死亡的主要原因。非小细胞肺癌(NSCLC)占大多数肺癌病例,约三分之一的患者在诊断时为 III 期疾病。由于这些患者的肿瘤大小和淋巴结分期不同,可以采用多种治疗方案,因此 III 期 NSCLC 的管理具有挑战性。在过去的几十年中,多学科团队(MDT)已在医疗保健服务中实施,以协调参与癌症治疗的不同医疗保健专业人员的行动。本综述的目的是讨论 MDT 对 III 期 NSCLC 管理、生存和生活质量的实际影响的证据。在这里,我们进行了文献回顾,以调查营养和导航护理在 NSCLC 护理中的作用以及 MDT 在治疗方案选择中的影响,包括免疫治疗巩固以及化疗和放疗相关不良事件的管理。我们还进行了映射审查,以确定全球医疗保健服务中癌症护理 MDT 实施方面的差距。